Table 1. Demographic, clinical outcomes, and cause of death after tocilizumab.

AA, African American; AHRF, acute hypoxic respiratory failure; CRP, C-reactive protein

No.	Age, years	Gender	Race	No. of days of symptoms	No. of days from symptoms to tocilizumab	Therapeutic anticoagulation	Outcome	Cause of death
1	38	Male	Hispanic	7	11	Yes	Survived	-
2	41	Male	Hispanic	3	3	Yes	Survived	-
3	43	Female	Hispanic	9	11	Yes	Survived	-
4	44	Male	Other	10	10	Yes	Survived	-
5	44	Male	Hispanic	7	11	Yes	Survived	-
6	46	Male	Hispanic	7	9	Yes	Survived	-
7	50	Male	Other	14	19	Yes	Survived	-
8	57	Male	Hispanic	14	16	Yes	Survived	-
9	60	Female	AA	7	10	Yes	Survived	-
10	60	Female	Hispanic	7	10	Yes	Survived	-
11	61	Female	Other	14	15	Yes	Survived	-
12	67	Male	AA	5	10	Yes	Survived	-
13	34	Male	Hispanic	7	10	No	Survived	-
14	44	Female	Other	3	3	No	Survived	-
15	60	Female	Hispanic	7	7	No	Survived	-
16	37	Male	Hispanic	2	3	Yes	Expired	Septic shock with acute rise of CRP/ferritin
17	42	Male	Hispanic	5	9	Yes	Expired	AHRF likely due to thromboembolic event
18	49	Male	Hispanic	7	8	Yes	Expired	Septic shock and multiorgan failure increasing pressor requirement (three pressors)
19	52	Male	Hispanic	7	9	Yes	Expired	Septic shock (blood culture positive for Neisseria sicca)
20	62	Male	Hispanic	7	14	Yes	Expired	Septic shock with increasing CRP/ferritin
21	35	Male	Hispanic	14	18	No	Expired	AHRF likely due to thromboembolic event
22	39	Male	Hispanic	7	8	No	Expired	AHRF likely due to thromboembolic event
23	52	Male	Hispanic	5	7	No	Expired	Septic shock and severe Clostridiodes difficile
24	60	Male	Hispanic	7	10	No	Expired	AHRF likely due to thromboembolic event